Identification of a Potential Biomarker for FABP4 Inhibition The Power of Lipidomics in Preclinical Drug Testing - Bertin Instruments

    Scientific publications

    Identification of a Potential Biomarker for FABP4 Inhibition The Power of Lipidomics in Preclinical Drug Testing

    Karsten Suhre1,2⇓ Werner Römisch-Margl1 Martin Hrabé de Angelis3,4 Jerzy Adamski3,4 Gerd Luippold5 Robert Augustin5
    Sources: 1Institute for Bioinformatics and Systems Biology, Helmholtz Zentrum München, German Research Center for Environment,al Health, Neuherberg, Germany 2Faculty of Biology, Ludwig-Maximilians-Universität, Planegg-Martinsried, Germany 3Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environment,al Health, Neuherberg, Germany 4Institute of Experimental Genetics, Life and Food Science Center Weihenstephan, Technische Universität München, Freising-Weihenstephan, Germany 5Department of Cardiometabolic Diseases Research, Boehringer Ingelheim Pharma GmbH &Co KG, Biberach a.d. Riss, Germany
    May 4, 2011, doi: 10.1177/1087057111402200 J Biomol Screen June 2011 vol. 16 no. 5 467-475

    Sample name

    Animal tissues (adipose tissue of mice)

    ANY QUESTIONS? CONTACT AN EXPERT

    Please fill in this form if you wish to contact our sales team or receive further information.

    My Account
    Forgot password ?

    Add a question !

    Add a question